Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.51 |
| ▸ | PYGL | P06737 | 3/20 | 0.50 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9281232 | 1.00 | MAP3K14 (0.51) | MAP3K14PYGLSRD5A1SRD5A2HTR2C | |
| SCHEMBL29959450 | 1.00 | MAP3K14 (0.51) | MAP3K14PYGLSRD5A1SRD5A2HTR2C | |
| SCHEMBL1693312 | 1.00 | MAP3K14 (0.51) | MAP3K14PYGLSRD5A1SRD5A2HTR2C | |
| SCHEMBL23850632 | 0.89 | PYGL (0.52) | MAP3K14PYGLSRD5A1SRD5A2HTR2C | |
| SCHEMBL15778906 | 0.89 | PYGL (0.52) | MAP3K14PYGLSRD5A1SRD5A2HTR2C | |
| SCHEMBL1745279 | 0.85 | GFRA3 (0.50) | MAP3K14PYGLSRD5A1PGRGFRA3 | |
| SCHEMBL1154693 | 0.84 | MAP3K14 (0.47) | MAP3K14PYGLSRD5A1HTR2CHTR2A | |
| SCHEMBL1154652 | 0.84 | MAP3K14 (0.47) | MAP3K14PYGLSRD5A1HTR2CHTR2A | |
| SCHEMBL1155475 | 0.84 | MAP3K14 (0.47) | MAP3K14PYGLSRD5A1HTR2CHTR2A | |
| SCHEMBL7442811 | 0.82 | ESR2 (0.54) | HTR2BPGRTSHRSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | MAP3K14 1577/4885PYGL 3191/4885SRD5A1 4195/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | MAP3K14 1577/4885PYGL 3191/4885SRD5A1 4195/4885 |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | MAP3K14 1545/4885PYGL 317/4885SRD5A1 1563/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | MAP3K14 1577/4885PYGL 3191/4885SRD5A1 4195/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | MAP3K14 1577/4885PYGL 3191/4885SRD5A1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.